NIRAVAM Drug Patent Profile

✉ Email this page to a colleague

When do Niravam patents expire, and what generic alternatives are available?

Niravam is a drug marketed by Ucb Inc and is included in one NDA.

The generic ingredient in NIRAVAM is alprazolam. There are fifteen drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the alprazolam profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Niravam

A generic version of NIRAVAM was approved as alprazolam by NOVITIUM PHARMA on October 19^th, 1993.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for NIRAVAM?
What are the global sales for NIRAVAM?
What is Average Wholesale Price for NIRAVAM?

Summary for NIRAVAM

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	53
Clinical Trials:	3
Patent Applications:	4,484
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NIRAVAM
What excipients (inactive ingredients) are in NIRAVAM?	NIRAVAM excipients list
DailyMed Link:	NIRAVAM at DailyMed

Drug patent expirations by year for NIRAVAM

Recent Clinical Trials for NIRAVAM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Actavis Inc.	Phase 1
UCB Pharma	Phase 4

See all NIRAVAM clinical trials

Paragraph IV (Patent) Challenges for NIRAVAM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NIRAVAM	Orally Disintegrating Tablets	alprazolam	0.25 mg, 0.5 mg, 1 mg and 2 mg	021726	1	2005-12-27

US Patents and Regulatory Information for NIRAVAM

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ucb Inc	NIRAVAM	alprazolam	TABLET, ORALLY DISINTEGRATING;ORAL	021726-001	Jan 19, 2005		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Ucb Inc	NIRAVAM	alprazolam	TABLET, ORALLY DISINTEGRATING;ORAL	021726-004	Jan 19, 2005		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Ucb Inc	NIRAVAM	alprazolam	TABLET, ORALLY DISINTEGRATING;ORAL	021726-002	Jan 19, 2005		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for NIRAVAM

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ucb Inc	NIRAVAM	alprazolam	TABLET, ORALLY DISINTEGRATING;ORAL	021726-002	Jan 19, 2005	⤷ Sign Up	⤷ Sign Up
Ucb Inc	NIRAVAM	alprazolam	TABLET, ORALLY DISINTEGRATING;ORAL	021726-001	Jan 19, 2005	⤷ Sign Up	⤷ Sign Up
Ucb Inc	NIRAVAM	alprazolam	TABLET, ORALLY DISINTEGRATING;ORAL	021726-004	Jan 19, 2005	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for NIRAVAM

See the table below for patents covering NIRAVAM around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Hong Kong	1137654		⤷ Sign Up
European Patent Office	2147669	Formule de dosage robuste à dissolution rapide (Rapidly dissolving robust dosage form)	⤷ Sign Up
Australia	726336		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for NIRAVAM

Recent Clinical Trials for NIRAVAM

Paragraph IV (Patent) Challenges for NIRAVAM

Make Better Decisions: Try a trial or see plans & pricing